Risankizumab Tops Competitor for Clinical Remission in Moderate-to-Severe CD

[ad_1]

(MedPage Today) — SAN FRANCISCO — More adults with moderate-to-severe Crohn’s disease (CD) reached clinical remission after 6 months on risankizumab (Skyrizi) versus ustekinumab (Stelara), according to a head-to-head trial.
In the phase III…

[ad_2]

Source link : https://www.medpagetoday.com/meetingcoverage/ccc/114142

Author :

Publish date : 2025-02-08 19:03:49

Copyright for syndicated content belongs to the linked Source.